S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
Log in

NASDAQ:EMANeMagin Stock Price, Forecast & News

$1.41
+0.09 (+6.82 %)
(As of 08/11/2020 12:28 PM ET)
Add
Compare
Today's Range
$1.33
Now: $1.41
$1.46
50-Day Range
$0.75
MA: $0.95
$1.45
52-Week Range
$0.14
Now: $1.41
$1.64
Volume56,013 shs
Average Volume3.09 million shs
Market Capitalization$86.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
eMagin Corporation designs, develops, manufactures, and markets organic light emitting diode (OLED) displays on-silicon micro displays; virtual imaging products that utilize OLED micro displays; and related products. It offers super video graphics array (SVGA) + OLED micro displays; digital SVGA OLED-XL; super extended graphics array OLED-XL/XLS and OLED-XL; video graphics array OLED-XL; and widescreen ultra-extended graphics array OLED-XL/XLS. The company also provides design reference kits, which include a micro display and associated electronics to help original equipment manufacturers (OEMs) evaluate micro display products; near-eye virtual imaging modules that incorporate its OLED-on-silicon micro displays with its lenses and electronic interfaces for integration into OEM products; immersive head mounted display products; and night vision smartphone camera attachment and goggles. It serves OEMs in the military, aviation, and consumer market sectors. The company sells its products directly in North America, Asia, and Europe; and through distributors in Asia and South Korea. eMagin Corporation was founded in 1996 and is headquartered in Hopewell Junction, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Semiconductor Equipment & Materials
Sub-IndustryN/A
Current SymbolNASDAQ:EMAN
CUSIPN/A
CIKN/A
Phone845-838-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees103
Market Cap$86.31 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableOptionable
$1.41
+0.09 (+6.82 %)
(As of 08/11/2020 12:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EMAN News and Ratings via Email

Sign-up to receive the latest news and ratings for EMAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











eMagin (NASDAQ:EMAN) Frequently Asked Questions

How has eMagin's stock price been impacted by COVID-19?

eMagin's stock was trading at $0.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EMAN stock has increased by 464.0% and is now trading at $1.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of eMagin?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for eMagin in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for eMagin
.

When is eMagin's next earnings date?

eMagin is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for eMagin
.

How can I listen to eMagin's earnings call?

eMagin will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were eMagin's earnings last quarter?

eMagin Corporation (NASDAQ:EMAN) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.03) EPS for the quarter. The firm earned $6.73 million during the quarter.
View eMagin's earnings history
.

Has eMagin been receiving favorable news coverage?

Media headlines about EMAN stock have been trending neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. eMagin earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about eMagin
.

Who are some of eMagin's key competitors?

What other stocks do shareholders of eMagin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other eMagin investors own include Ibio (IBIO), Biocept (BIOC), Blink Charging (BLNK), Digital Ally (DGLY), Inpixon (INPX), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), FORESIGHT AUTON/S (FRSX), Guardion Health Sciences (GHSI) and AIM ImmunoTech (AIM).

Who are eMagin's key executives?

eMagin's management team includes the following people:
  • Mr. Andrew G. Sculley Jr., CEO & Director (Age 68)
  • Mr. Jeffrey P. Lucas, Pres, CFO & Chief Accounting Officer (Age 59)
  • Dr. Amalkumar Ghosh, Chief Technology Officer & Sr. VP (Age 65)
  • Mr. Olivier Prache, Sr. VP of Product Devel. (Age 60)
  • Mr. Joseph Saltarelli, Sr. VP of Manufacturing Operations (Age 51)

What is eMagin's stock symbol?

eMagin trades on the NASDAQ under the ticker symbol "EMAN."

How do I buy shares of eMagin?

Shares of EMAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is eMagin's stock price today?

One share of EMAN stock can currently be purchased for approximately $1.41.

How big of a company is eMagin?

eMagin has a market capitalization of $86.31 million. eMagin employs 103 workers across the globe.

What is eMagin's official website?

The official website for eMagin is emagin.com.

How can I contact eMagin?

The company can be reached via phone at 845-838-7900.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.